Fujisaki Natsumi, Suwazono Shugo, Suehara Masahito, Nakachi Ryo, Kido Miwako, Fujiwara Yoshihisa, Oshiro Saki, Tokashiki Takashi, Takashima Hiroshi, Nakagawa Masanori
Department of Neurology, National Hospital Organization Okinawa National Hospital, Ginowan, Japan.
Center for Clinical Neuroscience, National Hospital Organization Okinawa National Hospital, Ginowan, Japan.
Intractable Rare Dis Res. 2018 Feb;7(1):7-12. doi: 10.5582/irdr.2017.01084.
Hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P) is a motor and sensory neuronopathy with autosomal dominant inheritance, adult onset, slowly progressive course, and is associated with (TFG) mutation. At advanced stages, respiratory failure and dysphagia becomes life-threatoning, and patients typically die by their 70s. Although there is currently no evidence for effective treatment, a therapy may be found by elucidation of the function of TFG. Recently its pathomechanism has been proposed to be associated with abnormalities in protein transfer from the endoplasmic reticulum. Such pathomechanisms might involve a similar process in amyotrophic lateral sclerosis; thus, its pathomechanisms and treatment strategy might make it a good model for neurodegenerative disorders. It is of great value to clarify the natural history of HMSN-P, in oder to judge the treatment effect. By evaluating 97 patients (79 out of 97 were examined and all confirmed with p.Pro 285 Leu mutation) in this study, it was confirmed that this disease follows a uniform course in the earlier stages, and there are individual differences in the onset between 20 and 30 years. Such uniformity might be due to the proposed single gene abnormality. At advanced stages, there are larger individual differences in the progression, but the reasons for these are unknown. Longer survival might be achieved with a better care for respiratory failure and dysphagia if such cares were undertaken at appropriate times.
遗传性运动和感觉神经病伴近端优势受累(HMSN-P)是一种运动和感觉神经元病,具有常染色体显性遗传、成人发病、病程缓慢进展的特点,且与(TFG)突变相关。在疾病晚期,呼吸衰竭和吞咽困难会危及生命,患者通常在70多岁时死亡。尽管目前尚无有效治疗的证据,但通过阐明TFG的功能可能会找到一种治疗方法。最近有人提出其发病机制与内质网蛋白质转运异常有关。这种发病机制可能与肌萎缩侧索硬化症中的类似过程有关;因此,其发病机制和治疗策略可能使其成为神经退行性疾病的一个良好模型。阐明HMSN-P的自然史对于判断治疗效果具有重要价值。通过对本研究中的97例患者(97例中有79例接受检查且均证实存在p.Pro 285 Leu突变)进行评估,证实该疾病在早期阶段病程一致,发病年龄在20至30岁之间存在个体差异。这种一致性可能归因于所提出的单基因异常。在晚期阶段,病情进展存在较大个体差异,但其原因尚不清楚。如果在适当的时候对呼吸衰竭和吞咽困难进行更好的护理,可能会延长生存期。